<DOC>
	<DOCNO>NCT02003547</DOCNO>
	<brief_summary>A Single Centre , Placebo-Controlled , Double-Masked , Sequential Designed Study Evaluate 3 Ophthalmic Formulations AMA0076 Healthy Subjects</brief_summary>
	<brief_title>A Single Centre Study Evaluate 3 Ophthalmic Formulations Healthy Subjects</brief_title>
	<detailed_description>Each subject receive follow treatment : - Period 1 : Formulation A ( n = 14 ) placebo ( n = 7 ) twice daily 7 day - Period 2 : Formulation B ( n = 14 ) placebo ( n = 7 ) twice daily 7 day - Period 3 : Formulation C ( n = 14 ) placebo ( n = 7 ) twice daily 7 day There minimum washout 7 day treatment period ( last dose previous period first dose subsequent period</detailed_description>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female , age 35 65 year . Body mass index â‰¤35kg/m2 . IOP 15 24 mmHg ( inclusive ) eye Screening Visits 1 2 . Women childbearing potential positive pregnancy test . Any subject deem investigator uncontrolled systemic hypertension Use systemic , inhale ocular corticosteroid treatment within 90 day screen likely require use study period . Any screening laboratory abnormality , either investigator 's medical monitor 's judgment , consider clinically significant safety risk . History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study , interfere interpretation subject 's study result . Participation clinical study within 1 month screening study . Receipt another investigational drug within 90 day dose study Diagnosis form glaucoma . IOP &gt; 24 mmHg either eye screening visit . Use ocular drop ( include lubricate drops/artificial tear ) screen period need ocular drop duration study participation . In opinion investigator , clinically significant eye trauma within 6 month screen . Any intraocular ophthalmic procedure within 6 month screen . Any ocular inflammation within 90 day screen history recurrent uveitis either eye . Subjects know ocular disease care hospital ophthalmologist . Any condition prevent valid applanation tonometry measurement . Unable discontinue contact lens wear study Visual acuity ( VA ) worse 20/80 either eye Subjects study site employee , immediate family member study site sponsor employee . History drug alcohol abuse past 2 year . Regular alcohol consumption . Positive drug abuse test result . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result Serious adverse reaction serious hypersensitivity drug formulation excipients Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>